MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa 15-10-2023, 20:03

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) 21-11-2024, 18:00

STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD 27-03-2023, 18:25